ERBB2 and breast cancer: Taken together, these findings indicate that although Cx43 GJIC is impaired during breast cancer malignancy in HER2+ cells that remain sensitive to HER2 inhibitor, likely due to downregulation of total Cx43 levels, GJIC is rescuable by Cx43 overexpression.